A study by researchers at Baylor College of Medicine, Houston and the Alzhiemer's Disease Cooperative Study reported on testing of 2,052 patients taking solanezumb was submitted at a
recent meeting of the Ameican Neurological Ass. in Boston, MA.
"The experimental medicine, solanezumba, improved by 34%, the cognitive skills of patients with mild Alzheimer's disease . Solanezumba which is in late stage testing is one of several experimental drugs designed to remove beta-amyloid from the brain. Beta-amyloid is believed to have a toxic
effect on normal brain function."
Professional help for mature adults and their caring but exhausted families.
No comments:
Post a Comment